Refine
Has Fulltext
- yes (11)
Is part of the Bibliography
- yes (11)
Document Type
- Journal article (11)
Language
- English (11)
Keywords
- Bordetella pertussis (3)
- 3D tissue model (2)
- SARS-CoV-2 (2)
- Adenylate cyclase toxin (1)
- Head and neck cancers (1)
- IL-6 (1)
- Neisseria gonorrhoeae (1)
- acetylsalicylic acid (1)
- adenocarcinoma of the lung (1)
- adenylate cyclase toxin (1)
Institute
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (11)
- Institut für Virologie und Immunbiologie (4)
- Klinik und Poliklinik für Hals-, Nasen- und Ohrenkrankheiten, plastische und ästhetische Operationen (4)
- Theodor-Boveri-Institut für Biowissenschaften (4)
- Pathologisches Institut (2)
- Institut für Organische Chemie (1)
- Klinik und Poliklinik für Nuklearmedizin (1)
- Klinik und Poliklinik für Thorax-, Herz- u. Thorakale Gefäßchirurgie (1)
To circumvent time-consuming clinical trials, testing whether existing drugs are effective inhibitors of SARS-CoV-2, has led to the discovery of Remdesivir. We decided to follow this path and screened approved medications "off-label" against SARS-CoV-2. Fluoxetine inhibited SARS-CoV-2 at a concentration of 0.8 mu g/ml significantly in these screenings, and the EC50 was determined with 387 ng/ml. Furthermore, Fluoxetine reduced viral infectivity in precision-cut human lung slices showing its activity in relevant human tissue targeted in severe infections. Fluoxetine treatment resulted in a decrease in viral protein expression. Fluoxetine is a racemate consisting of both stereoisomers, while the S-form is the dominant serotonin reuptake inhibitor. We found that both isomers show similar activity on the virus, indicating that the R-form might specifically be used for SARS-CoV-2 treatment. Fluoxetine inhibited neither Rabies virus, human respiratory syncytial virus replication nor the Human Herpesvirus 8 or Herpes simplex virus type 1 gene expression, indicating that it acts virus-specific. Moreover, since it is known that Fluoxetine inhibits cytokine release, we see the role of Fluoxetine in the treatment of SARS-CoV-2 infected patients of risk groups.